Introduction:
73-year-old cancer patient at Houston Methodist Hospital underwent a successful liver transplant after a novel antibiotic cleared a chronic bile duct infection caused by drug-resistant pathogens, marking a significant breakthrough in treating extreme-resistant infections.
Also Read: Hidden Gem: Market leader stock that holds 90% market share in airport lounges
Share price movement of Wockhardt:
On December 16, 2024, Wockhardt Ltd. opened at ₹1,415.00, up 1.30% from its previous close of ₹1,396.75. The stock reached a high of ₹1,536.40 (8.15%) and a low of ₹1,415.00. By 10:48 AM, it traded at ₹1,510.60, an 8.15% increase, with a market cap of ₹24,542.07 crore.
Zaynich™ enables successful liver transplant:
Zaynich™ (Zidebactam/Cefepime, WCK 5222) has enabled a 73-year-old cancer patient at Houston Methodist Hospital to undergo a successful liver transplant after it effectively cleared a chronic bile duct infection caused by drug-resistant pathogens. Zaynich™ is Wockhardt’s novel antibiotic, combining Zidebactam and Cefepime.
A bile duct cancer patient, unresponsive to six weeks of antibiotics, was treated with Zaynich™ under FDA’s compassionate use. The antibiotic eradicated resistant pathogens, enabling her liver transplant to proceed successfully.
Zaynich™’s success story marks another triumph in overcoming extreme-drug-resistant Gram-negative pathogens. With 45 patients benefiting from the treatment under compassionate use, the antibiotic showcases its vital role in saving lives in critical conditions.
Recent news on Wockhardt:
As of November 13, 2024, Wockhardt reported a consolidated net loss of ₹16 crore for Q2 FY24, improving from a ₹73 crore loss in the same quarter last year. Revenue increased to ₹809 crore, up from ₹753 crore.
Ace investor holding in Wockhardt:
Estate of late Mr. Rakesh Jhunjhunwala
Late Mr. Rakesh Jhunjhunwala held a 1.75% stake in Wockhardt Ltd, a total of 2,837,005 shares. These shares reflect his significant investment in the pharmaceutical company, contributing to his diverse portfolio in the stock market.
Stock performance of Wockhardt for Period of 1 week, 6 months and 1 year:
Wockhardt Ltd. has shown impressive performance with a 0.09% increase over the past week. Over the last 6 months, the stock surged by 144%, and over the past year, it delivered a remarkable 237% return, reflecting strong growth.
Also Read: 3 Stocks in which Govt of Singapore bought fresh stake in Q2 to look out for
Shareholding pattern of Wockhardt:
| All values in % | Sep 2024 | Jun 2024 | Mar 2024 |
| Promoter | 52.00% | 52.00% | 51.60% |
| FII | 6.70% | 5.90% | 5.50% |
| DII | 5.10% | 4.50% | 4.80% |
| Public | 36.20% | 37.60% | 38.10% |
About Wockhardt:
Wockhardt Ltd. (NSE: WOCKPHARMA) is a research-driven global pharmaceutical and biotech company. It specializes in antibacterial drug discovery, with six programs granted QIDP status by the USFDA to combat untreatable superbugs.
Disclaimer: The above article is written for educational purposes, and the companies’ data mentioned in the article may change with respect to time The securities quoted are exemplary and are not recommendatory.
